TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Illumina ( (ILMN) ) just unveiled an update.
On November 25, 2025, Illumina, Inc. completed a public offering of $500 million in 4.750% notes due 2030. The company plans to use the proceeds for general corporate purposes, including repaying existing debt and potentially completing the acquisition of SomaLogic, Inc., which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (ILMN) stock is a Buy with a $195.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Outperform.
Illumina’s strong performance in the earnings call and bullish technical indicators are the most significant factors driving the score. Financial performance shows recovery but is tempered by increased leverage and cash flow challenges. Valuation is reasonable, supporting a positive outlook.
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina, Inc. operates in the biotechnology industry, focusing on the development and manufacturing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Average Trading Volume: 1,733,784
Technical Sentiment Signal: Buy
Current Market Cap: $19.25B
See more insights into ILMN stock on TipRanks’ Stock Analysis page.